Does RUXOLITINIB Cause Malignant neoplasm progression? 321 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 321 reports of Malignant neoplasm progression have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.5% of all adverse event reports for RUXOLITINIB.
321
Reports of Malignant neoplasm progression with RUXOLITINIB
0.5%
of all RUXOLITINIB reports
130
Deaths
72
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RUXOLITINIB?
Of the 321 reports, 130 (40.5%) resulted in death, 72 (22.4%) required hospitalization, and 11 (3.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 321 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RUXOLITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE